Radiopharm Theranostics Announces Update On Pipeline Of Clinical Programs And Outlined Expected Milestones Through End Of 2025 And Into 2026

Author: Benzinga Newsdesk | October 20, 2025 08:03am

• Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from solid tumors, confirming proof-of-concept with Phase 2 topline results expected by H1 2026
   
• First cohort of patients in Phase 1 clinical trial of RAD 202 (HER2) shows higher than expected tumour uptake; Anticipates second cohort of patients to be fully enrolled with data available by year-end 2025
   
• Data from first six patients in Phase 1 clinical trial of RAD 204 (PDL-1) show promising tumor uptake, stable disease at the first dose level in two out of three patients
   
• Data from Phase 1 study with RAD 301 supports decision to advance to Phase 2 imaging trial in patients with loco-regional pancreatic cancer

SYDNEY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced an update on its pipeline of clinical programs and outlined expected milestones through the end of 2025 and into 2026.

Posted In: RADX